The Systemic Immune Inflammatory Response Index Can Predict the Clinical Prognosis of Patients with Initially Diagnosed Coronary Artery Disease

Abstract

Background Recently, the systemic immune inflammatory response index (SIIRI), a novel and expanded inflammatory response marker, has been an independent predictor of lesion severity in patients with acute coronary syndrome (ACS). However, its predictive role in patients with initially diagnosed coronary artery disease (CAD) remains to be explored. Patients and Methods We evaluated 959 patients with CAD undergoing an initial coronary intervention. Each patient had laboratory measurements, including blood cell counts, taken after admission and before interventional treatment. The primary endpoint was major cardiovascular events (MACEs), defined as cardiovascular death, nonfatal myocardial infarction(MI), and nonfatal stroke. The secondary endpoints included MACEs and readmission for congestive heart failure(HF). Results During a mean follow-up period of 33.3±9.9 months, 229 (23.9%) MACEs were recorded. ROC curve analysis displayed that the best cut-off value of SIIRI for predicting MACEs was 247.17*10 18 /L 2 . Kaplan-Meier survival curve analysis showed that the survival rate of the low SIIRI group was higher than that of the high SIIRI group (P<0.001). Compared with the low SIIRI group, the high SIIRI group had a significantly higher risk of MACEs (187 cases (39.53%) vs.42 patients (8.64%), P<0.001). Univariate and multivariate Cox regression analyses displayed that high SIIRI levels were independently associated with the occurrence of MACEs in patients with initially diagnosed CAD undergoing percutaneous coronary intervention (PCI) (adjusted hazard ratio [HR]: 3.808, 95% confidence interval [CI%]: 2.643–5.486, P<0.001). Adding SIIRI to conventional risk factor models improved the predictive value of MACEs. Conclusion Elevated SIIRI is associated with adverse cardiovascular prognosis in patients with initially diagnosed CAD. SIIRI can be a simple and practical index to identify high-risk patients with CAD after PCI.

Systemic immune-inflammation index and its relation to blood pressure and dyslipidemia in adults: A retrospective study

“…The systemic immune-inflammation index (SII) is a prognostic and predictive score calculated using platelets, lymphocytes, and neutrophil levels. [8] Initially developed for determining prognoses for patients following surgery for hepatocellular carcinoma, [8] it has since been examined as an inflammatory marker for several health outcomes [9–23] and mortality. [24–27] A recent systematic review and meta-analysis indicated that SII was significantly associated with cardiovascular disease risk (e.g., stroke, myocardial infarction, peripheral arterial disease), and levels of SII were significantly higher at disease onset than among individuals in the general population.…”

The Systemic Inflammation Index Predicts Poor Clinical Prognosis in Patients with Initially Diagnosed Acute Coronary Syndrome Undergoing Primary Coronary Angiography

“…50 Similarly, our previous studies have also confirmed that SIIRI is associated with adverse cardiovascular prognosis in patients with initially diagnosed CAD, suggesting that SIIRI may be a valuable predictor of adverse prognosis in patients with initially diagnosed CAD. 51 In future studies, SIIRI may also become a valuable predictor of inflammation, and the predictive ability of SIIRI with SII in different patient populations needs to be investigated.…”